IRVINE, Calif., May 2 /PRNewswire/ — Seragon Biosciences, Inc. today announced the
launch of RESTORIN®, an advanced nutraceutical for
healthy aging. RESTORIN integrates a number of patented technologies
Harvard University, the Mayo Clinic, and Scripps Research, which
increase cellular nicotinamide adenine dinucleotide (NAD+) levels and the
enhance senolytic stimulation.
launch of RESTORIN®, an advanced nutraceutical for
healthy aging. RESTORIN integrates a number of patented technologies
Harvard University, the Mayo Clinic, and Scripps Research, which
increase cellular nicotinamide adenine dinucleotide (NAD+) levels and the
enhance senolytic stimulation.
For decades, the complicated nature of aging has plagued scientists
many obstacles stand in the way in the field of aging intervention. The newest
Research results have identified senolytics and NAD+ as key technologies
identified to address this challenge. RESTORIN is a senolytic
Controlled Release NAD+ Booster. It also uses the
Seragon’s SERC(TM) targeted release technology, utilizing hydrophilic and
lipophilic vehicle and a pH responsive enteric vehicle
Delivery system used to ensure the bioavailability of the ingredients
to improve.